Clinical trial readout dates for Immunovant Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is May 2027.
| Phase 2 IMVT-1402 Graves' Disease · NCT07018323 | May 2027 Recruiting |
| Phase 2 IMVT-1402 Rheumatoid Arthritis · NCT06754462 | September 2027 Ongoing |
| Phase 3 IMVT-1402 Generalized Myasthenia Gravis · NCT07039916 | December 2027 Recruiting |
| Phase 2 IMVT-1402 Graves' Disease · NCT06727604 | June 2028 Recruiting |
| Phase 2 IMVT-1402 Primary Sjögren's Syndrome · NCT06979531 | July 2028 Ongoing |
| Phase 2 Imeroprubart Chronic Inflammatory Demyelinating Polyneuropathy · NCT07032662 | August 2028 Recruiting |
| Phase 2 IMVT-1402 Graves' Disease · NCT07286006 | March 2030 Enrolling |
Immunovant Inc. reported $722M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-09). Its net loss for that quarter was $97M; at that rate the cash would last about 7 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-09 |